• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4602587)   Today's Articles (2342)   Subscriber (49368)
For: Spira AI, Stewart MD, Jones S, Chang E, Fielding A, Richie N, Wood LS, Thompson MA, Jones L, Nair A, Mahal BA, Gerber DE. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group. Clin Cancer Res 2021;27:2416-2423. [PMID: 33563636 DOI: 10.1158/1078-0432.ccr-20-3853] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 11/25/2020] [Accepted: 12/22/2020] [Indexed: 11/16/2022]
Number Cited by Other Article(s)
1
Xiao H, Vaidya R, Hershman DL, Unger JM. Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022. J Clin Oncol 2024;42:1953-1960. [PMID: 38537158 DOI: 10.1200/jco.23.01777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 01/12/2024] [Accepted: 02/08/2024] [Indexed: 05/31/2024]  Open
2
Ruiz J, Kelly RK, Aplenc R, Laetsch TW, Seif AE. Absolute neutrophil count clinical trial eligibility criteria for pediatric oncology phase I and phase I/II trials by sponsorship. Pediatr Blood Cancer 2024;71:e30925. [PMID: 38409529 DOI: 10.1002/pbc.30925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 02/03/2024] [Accepted: 02/09/2024] [Indexed: 02/28/2024]
3
Budhu JA, Chukwueke UN, Jackson S, Lee EQ, McFaline-Figueroa JR, Willmarth N, Dalmage M, Kawachi I, Arons D, Chang SM, Galanis E, Hervey-Jumper SL, Wen PY, Porter AB. Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort. Neuro Oncol 2024;26:596-608. [PMID: 38071654 PMCID: PMC10995510 DOI: 10.1093/neuonc/noad242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/06/2024]  Open
4
Hoin JA, Carthon BC, Brown SJ, Durham LM, Garrot LC, Ghamande SA, Pippas AW, Rivers BM, Snyder CT, Gabram-Mendola SGA. Addressing disparities in cancer clinical trials: a roadmap to more equitable accrual. FRONTIERS IN HEALTH SERVICES 2024;4:1254294. [PMID: 38523649 PMCID: PMC10957576 DOI: 10.3389/frhs.2024.1254294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Accepted: 02/27/2024] [Indexed: 03/26/2024]
5
Hartley-Brown M, Cole CE, Price P, Andreini M, Mulligan G, Young AQ, Cho HJ. Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2024;24:32-39. [PMID: 37783639 DOI: 10.1016/j.clml.2023.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 09/07/2023] [Accepted: 09/11/2023] [Indexed: 10/04/2023]
6
Praiss AM, Miller A, Smith J, Lichtman SM, Bookman M, Aghajanian C, Sabbatini P, Backes F, Cohn DE, Argenta P, Friedlander M, Goodheart MJ, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray H, Secord AA, Van Le L, O'Cearbhaill RE. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study. Gynecol Oncol 2023;174:213-223. [PMID: 37229879 PMCID: PMC10330633 DOI: 10.1016/j.ygyno.2023.05.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Revised: 05/11/2023] [Accepted: 05/12/2023] [Indexed: 05/27/2023]
7
Versavel S, Subasinghe A, Johnson K, Golonski N, Muhlhausen J, Perry P, Sanchez R. Diversity, equity, and inclusion in clinical trials: A practical guide from the perspective of a trial sponsor. Contemp Clin Trials 2023;126:107092. [PMID: 36702295 DOI: 10.1016/j.cct.2023.107092] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 12/15/2022] [Accepted: 01/17/2023] [Indexed: 01/24/2023]
8
Washington V, Franklin JB, Huang ES, Mega JL, Abernethy AP. Diversity, Equity, and Inclusion in Clinical Research: A Path Toward Precision Health for Everyone. Clin Pharmacol Ther 2023;113:575-584. [PMID: 36423203 DOI: 10.1002/cpt.2804] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2022] [Accepted: 11/18/2022] [Indexed: 11/25/2022]
9
Chang SK, Liu D, Mitchem J, Papageorgiou C, Kaifi J, Shyu CR. Understanding common key indicators of successful and unsuccessful cancer drug trials using a contrast mining framework on ClinicalTrials.gov. J Biomed Inform 2023;139:104321. [PMID: 36806327 DOI: 10.1016/j.jbi.2023.104321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Revised: 02/04/2023] [Accepted: 02/11/2023] [Indexed: 02/18/2023]
10
Riner AN, Freudenberger DC, Herremans KM, Vudatha V, Neal DW, George TJ, Trevino JG. Call to action: overcoming enrollment disparities in cancer clinical trials with modernized eligibility criteria. JNCI Cancer Spectr 2023;7:7049523. [PMID: 36806713 PMCID: PMC9978314 DOI: 10.1093/jncics/pkad009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Revised: 12/26/2022] [Accepted: 02/03/2023] [Indexed: 02/23/2023]  Open
11
Chen J, Lu Y, Kummar S. Increasing patient participation in oncology clinical trials. Cancer Med 2023;12:2219-2226. [PMID: 36043431 PMCID: PMC9939168 DOI: 10.1002/cam4.5150] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Accepted: 08/08/2022] [Indexed: 11/11/2022]  Open
12
Stensland KD, Richesson RL, Vince RA, Skolarus TA, Sales AE. Evolving a national clinical trials learning health system. Learn Health Syst 2022;7:e10327. [PMID: 37066100 PMCID: PMC10091198 DOI: 10.1002/lrh2.10327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 05/26/2022] [Accepted: 06/28/2022] [Indexed: 11/07/2022]  Open
13
Rafee A, Riepenhausen S, Neuhaus P, Meidt A, Dugas M, Varghese J. ELaPro, a LOINC-mapped core dataset for top laboratory procedures of eligibility screening for clinical trials. BMC Med Res Methodol 2022;22:141. [PMID: 35568796 PMCID: PMC9107639 DOI: 10.1186/s12874-022-01611-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Accepted: 04/20/2022] [Indexed: 12/21/2022]  Open
14
Benbow JH, Rivera DR, Lund JL, Feldman JE, Kim ES. Increasing Inclusiveness of Patient-Centric Clinical Evidence Generation in Oncology: Real-World Data and Clinical Trials. Am Soc Clin Oncol Educ Book 2022;42:1-11. [PMID: 35561304 DOI: 10.1200/edbk_350574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
15
Haynes RM, Sirintrapun SJ, Gao J, McKenzie AJ. Using Technology to Enhance Cancer Clinical Trial Participation. Am Soc Clin Oncol Educ Book 2022;42:1-7. [PMID: 35486887 DOI: 10.1200/edbk_349671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
16
Garrick O, Mesa R, Ferris A, Kim ES, Mitchell E, Brawley OW, Carpten J, Carter KD, Coney J, Winn R, Monroe S, Sandoval F, Perez E, Williams M, Grove E, Highsmith Q, Richie N, Begelman SM, Collins AS, Freedman J, Gonzales MS, Wilson G. Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical Trials. Ethn Dis 2022;32:61-68. [PMID: 35106045 PMCID: PMC8785867 DOI: 10.18865/ed.32.1.61] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2023]  Open
17
Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. J Cancer Policy 2021;30:100305. [DOI: 10.1016/j.jcpo.2021.100305] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2021] [Revised: 08/27/2021] [Accepted: 08/31/2021] [Indexed: 11/21/2022]
18
Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria. Ann Oncol 2021;32:950-953. [PMID: 33991601 DOI: 10.1016/j.annonc.2021.05.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 04/26/2021] [Accepted: 05/10/2021] [Indexed: 11/23/2022]  Open
19
Giantonio BJ. Eligibility in Cancer Clinical Research: The Intersection of Discovery, Generalizability, Beneficence, and Justice. Clin Cancer Res 2021;27:2369-2371. [PMID: 33602680 DOI: 10.1158/1078-0432.ccr-21-0085] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 02/09/2021] [Accepted: 02/15/2021] [Indexed: 11/16/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA